Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 128

1.

Treatment-Free Survival: A Novel Outcome Measure of the Effects of Immune Checkpoint Inhibition-A Pooled Analysis of Patients With Advanced Melanoma.

Regan MM, Werner L, Rao S, Gupte-Singh K, Hodi FS, Kirkwood JM, Kluger HM, Larkin J, Postow MA, Ritchings C, Sznol M, Tarhini AA, Wolchok JD, Atkins MB, McDermott DF.

J Clin Oncol. 2019 Sep 9:JCO1900345. doi: 10.1200/JCO.19.00345. [Epub ahead of print]

PMID:
31498030
2.

Absolute lymphocyte count as a prognostic biomarker for overall survival in patients with advanced melanoma treated with ipilimumab.

Postow MA, Chasalow SD, Kuk D, Panageas KS, Cheng ML, Yuan J, Wolchok JD.

Melanoma Res. 2019 Aug 14. doi: 10.1097/CMR.0000000000000633. [Epub ahead of print]

PMID:
31425479
3.

Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium.

Amaria RN, Menzies AM, Burton EM, Scolyer RA, Tetzlaff MT, Antdbacka R, Ariyan C, Bassett R, Carter B, Daud A, Faries M, Fecher LA, Flaherty KT, Gershenwald JE, Hamid O, Hong A, Kirkwood JM, Lo S, Margolin K, Messina J, Postow MA, Rizos H, Ross MI, Rozeman EA, Saw RPM, Sondak V, Sullivan RJ, Taube JM, Thompson JF, van de Wiel BA, Eggermont AM, Davies MA; International Neoadjuvant Melanoma Consortium members, Ascierto PA, Spillane AJ, van Akkooi ACJ, Wargo JA, Blank CU, Tawbi HA, Long GV.

Lancet Oncol. 2019 Jul;20(7):e378-e389. doi: 10.1016/S1470-2045(19)30332-8. Review.

PMID:
31267972
4.

Treatment Outcomes of Immune-Related Cutaneous Adverse Events.

Phillips GS, Wu J, Hellmann MD, Postow MA, Rizvi NA, Freites-Martinez A, Chan D, Dusza S, Motzer RJ, Rosenberg JE, Callahan MK, Chapman PB, Geskin L, Lopez AT, Reed VA, Fabbrocini G, Annunziata MC, Kukoyi O, Pabani A, Yang CH, Chung WH, Markova A, Lacouture ME.

J Clin Oncol. 2019 Jun 19:JCO1802141. doi: 10.1200/JCO.18.02141. [Epub ahead of print]

PMID:
31216228
5.

Toxicities of checkpoint inhibitors: causes and management.

Postow MA.

Clin Adv Hematol Oncol. 2019 Apr;17(4):220-222. No abstract available.

PMID:
31188813
6.

Rational design of anti-GITR-based combination immunotherapy.

Zappasodi R, Sirard C, Li Y, Budhu S, Abu-Akeel M, Liu C, Yang X, Zhong H, Newman W, Qi J, Wong P, Schaer D, Koon H, Velcheti V, Hellmann MD, Postow MA, Callahan MK, Wolchok JD, Merghoub T.

Nat Med. 2019 May;25(5):759-766. doi: 10.1038/s41591-019-0420-8. Epub 2019 Apr 29.

PMID:
31036879
7.

Myocarditis Surveillance in Patients with Advanced Melanoma on Combination Immune Checkpoint Inhibitor Therapy: The Memorial Sloan Kettering Cancer Center Experience.

Lee Chuy K, Oikonomou EK, Postow MA, Callahan MK, Chapman PB, Shoushtari AN, Neilan TG, Fradley MG, Ramanathan LV, Wolchok JD, Steingart RM, Gupta D.

Oncologist. 2019 May;24(5):e196-e197. doi: 10.1634/theoncologist.2019-0040. Epub 2019 Mar 25. No abstract available.

PMID:
30910868
8.

Safety of Inactivated Influenza Vaccine in Cancer Patients Receiving Immune Checkpoint Inhibitors (ICI).

Chong CR, Park VJ, Cohen B, Postow MA, Wolchok JD, Kamboj M.

Clin Infect Dis. 2019 Mar 15. pii: ciz202. doi: 10.1093/cid/ciz202. [Epub ahead of print]

PMID:
30874791
9.

Evaluation of the Response of Unresectable Primary Cutaneous Melanoma to Immunotherapy Visualized With Reflectance Confocal Microscopy: A Report of 2 Cases.

Navarrete-Dechent C, Cordova M, Postow MA, Pulitzer M, Lezcano C, Halpern AC, Rossi AM.

JAMA Dermatol. 2019 Mar 1;155(3):347-352. doi: 10.1001/jamadermatol.2018.3688.

PMID:
30624578
10.

Trial Reporting in Immuno-Oncology (TRIO): an American society of clinical oncology-society for immunotherapy of cancer statement.

Tsimberidou AM, Levit LA, Schilsky RL, Averbuch SD, Chen D, Kirkwood JM, McShane LM, Sharon E, Mileham KF, Postow MA.

J Immunother Cancer. 2018 Oct 19;6(1):108. doi: 10.1186/s40425-018-0426-7.

11.

Trial Reporting in Immuno-Oncology (TRIO): An American Society of Clinical Oncology-Society for Immunotherapy of Cancer Statement.

Tsimberidou AM, Levit LA, Schilsky RL, Averbuch SD, Chen D, Kirkwood JM, McShane LM, Sharon E, Mileham KF, Postow MA.

J Clin Oncol. 2019 Jan 1;37(1):72-80. doi: 10.1200/JCO.18.00145. Epub 2018 Oct 19.

12.

Tumor Board Conferences for Multidisciplinary Skin Cancer Management: A Survey of US Cancer Centers.

Mori S, Navarrete-Dechent C, Petukhova TA, Lee EH, Rossi AM, Postow MA, Dunn LA, Roman BR, Yin VT, Coit DG, Hollmann TJ, Busam KJ, Nehal KS, Barker CA.

J Natl Compr Canc Netw. 2018 Oct;16(10):1209-1215. doi: 10.6004/jnccn.2018.7044.

PMID:
30323091
13.

Non-conventional Inhibitory CD4+Foxp3-PD-1hi T Cells as a Biomarker of Immune Checkpoint Blockade Activity.

Zappasodi R, Budhu S, Hellmann MD, Postow MA, Senbabaoglu Y, Manne S, Gasmi B, Liu C, Zhong H, Li Y, Huang AC, Hirschhorn-Cymerman D, Panageas KS, Wherry EJ, Merghoub T, Wolchok JD.

Cancer Cell. 2018 Oct 8;34(4):691. doi: 10.1016/j.ccell.2018.09.007. No abstract available.

PMID:
30300585
14.

Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain.

Tawbi HA, Forsyth PA, Algazi A, Hamid O, Hodi FS, Moschos SJ, Khushalani NI, Lewis K, Lao CD, Postow MA, Atkins MB, Ernstoff MS, Reardon DA, Puzanov I, Kudchadkar RR, Thomas RP, Tarhini A, Pavlick AC, Jiang J, Avila A, Demelo S, Margolin K.

N Engl J Med. 2018 Aug 23;379(8):722-730. doi: 10.1056/NEJMoa1805453.

15.

Perspectives in melanoma: Meeting report from the Melanoma Bridge (30 November-2 December, 2017, Naples, Italy).

Ascierto PA, Puzanov I, Agarwala SS, Bifulco C, Botti G, Caracò C, Ciliberto G, Davies MA, Dummer R, Ferrone S, Gajewski TF, Garbe C, Luke JJ, Marincola FM, Masucci G, Mehnert JM, Mozzillo N, Palmieri G, Postow MA, Schoenberger SP, Wang E, Thurin M.

J Transl Med. 2018 Jul 21;16(1):207. doi: 10.1186/s12967-018-1568-6.

16.

MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma.

Rodig SJ, Gusenleitner D, Jackson DG, Gjini E, Giobbie-Hurder A, Jin C, Chang H, Lovitch SB, Horak C, Weber JS, Weirather JL, Wolchok JD, Postow MA, Pavlick AC, Chesney J, Hodi FS.

Sci Transl Med. 2018 Jul 18;10(450). pii: eaar3342. doi: 10.1126/scitranslmed.aar3342.

PMID:
30021886
17.

Bigger Is Not Always Better: Tumor Size and Prognosis in Advanced Melanoma.

Warner AB, Postow MA.

Clin Cancer Res. 2018 Oct 15;24(20):4915-4917. doi: 10.1158/1078-0432.CCR-18-1311. Epub 2018 Jun 14.

PMID:
29903895
18.

Non-conventional Inhibitory CD4+Foxp3-PD-1hi T Cells as a Biomarker of Immune Checkpoint Blockade Activity.

Zappasodi R, Budhu S, Hellmann MD, Postow MA, Senbabaoglu Y, Manne S, Gasmi B, Liu C, Zhong H, Li Y, Huang AC, Hirschhorn-Cymerman D, Panageas KS, Wherry EJ, Merghoub T, Wolchok JD.

Cancer Cell. 2018 Jun 11;33(6):1017-1032.e7. doi: 10.1016/j.ccell.2018.05.009. Erratum in: Cancer Cell. 2018 Oct 8;34(4):691.

19.

Does adjuvant therapy for high-risk melanoma with either immunotherapy or targeted therapy affect therapeutic choices at relapse?

Postow MA.

Clin Adv Hematol Oncol. 2018 May;16(5):353-355. No abstract available.

PMID:
29851931
20.

Combination Controversies: Checkpoint Inhibition Alone or in Combination for the Treatment of Melanoma?

Warner AB, Postow MA.

Oncology (Williston Park). 2018 May 15;32(5):228-34. Review.

21.

Immune-related Adverse Events in Cancer Patients.

Pallin DJ, Baugh CW, Postow MA, Caterino JM, Erickson TB, Lyman GH.

Acad Emerg Med. 2018 Jul;25(7):819-827. doi: 10.1111/acem.13443. Epub 2018 May 25. Review.

22.

Adverse Events Associated with Immune Checkpoint Blockade.

Postow MA, Hellmann MD.

N Engl J Med. 2018 Mar 22;378(12):1165. doi: 10.1056/NEJMc1801663. No abstract available.

PMID:
29562154
23.

The brim of uncertainty in adjuvant treatment of melanoma.

Warner AB, Postow MA.

Lancet Oncol. 2018 Apr;19(4):436-437. doi: 10.1016/S1470-2045(18)30150-5. Epub 2018 Feb 21. No abstract available.

PMID:
29477664
24.

Peripheral blood clinical laboratory variables associated with outcomes following combination nivolumab and ipilimumab immunotherapy in melanoma.

Rosner S, Kwong E, Shoushtari AN, Friedman CF, Betof AS, Brady MS, Coit DG, Callahan MK, Wolchok JD, Chapman PB, Panageas KS, Postow MA.

Cancer Med. 2018 Mar;7(3):690-697. doi: 10.1002/cam4.1356. Epub 2018 Feb 22.

25.

Clinical Development of PD-1 in Advanced Melanoma.

Munhoz RR, Postow MA.

Cancer J. 2018 Jan/Feb;24(1):7-14. doi: 10.1097/PPO.0000000000000299. Review.

26.

Reply to M. Horiguchi et al.

Schadendorf D, Jiang J, Kelleher T, Postow MA.

J Clin Oncol. 2018 Mar 1;36(7):721. doi: 10.1200/JCO.2017.76.5339. Epub 2018 Jan 16. No abstract available.

PMID:
29337639
27.

LXR/ApoE Activation Restricts Innate Immune Suppression in Cancer.

Tavazoie MF, Pollack I, Tanqueco R, Ostendorf BN, Reis BS, Gonsalves FC, Kurth I, Andreu-Agullo C, Derbyshire ML, Posada J, Takeda S, Tafreshian KN, Rowinsky E, Szarek M, Waltzman RJ, Mcmillan EA, Zhao C, Mita M, Mita A, Chmielowski B, Postow MA, Ribas A, Mucida D, Tavazoie SF.

Cell. 2018 Feb 8;172(4):825-840.e18. doi: 10.1016/j.cell.2017.12.026. Epub 2018 Jan 11.

28.

Immune-Related Adverse Events Associated with Immune Checkpoint Blockade.

Postow MA, Sidlow R, Hellmann MD.

N Engl J Med. 2018 Jan 11;378(2):158-168. doi: 10.1056/NEJMra1703481. Review. No abstract available.

PMID:
29320654
29.

High response rate to PD-1 blockade in desmoplastic melanomas.

Eroglu Z, Zaretsky JM, Hu-Lieskovan S, Kim DW, Algazi A, Johnson DB, Liniker E, Ben Kong, Munhoz R, Rapisuwon S, Gherardini PF, Chmielowski B, Wang X, Shintaku IP, Wei C, Sosman JA, Joseph RW, Postow MA, Carlino MS, Hwu WJ, Scolyer RA, Messina J, Cochran AJ, Long GV, Ribas A.

Nature. 2018 Jan 18;553(7688):347-350. doi: 10.1038/nature25187. Epub 2018 Jan 10.

30.

Langerhans-type dendritic cells electroporated with TRP-2 mRNA stimulate cellular immunity against melanoma: Results of a phase I vaccine trial.

Chung DJ, Carvajal RD, Postow MA, Sharma S, Pronschinske KB, Shyer JA, Singh-Kandah S, Dickson MA, D'Angelo SP, Wolchok JD, Young JW.

Oncoimmunology. 2017 Sep 21;7(1):e1372081. doi: 10.1080/2162402X.2017.1372081. eCollection 2017.

31.

Four-month course of adjuvant dabrafenib in patients with surgically resected stage IIIC melanoma characterized by a BRAFV600E/K mutation.

Momtaz P, Harding JJ, Ariyan C, Coit DG, Merghoub T, Gasmi B, You D, Viale A, Panageas KS, Samoila A, Postow MA, Wolchok JD, Chapman PB.

Oncotarget. 2017 Sep 16;8(62):105000-105010. doi: 10.18632/oncotarget.21072. eCollection 2017 Dec 1.

32.

Treatment of advanced melanoma - A changing landscape.

Hepner A, Salgues A, Anjos CAD, Sahade M, Camargo VP, Garicochea B, Shoushtari AN, Postow MA, Fernandes GS, Munhoz RR.

Rev Assoc Med Bras (1992). 2017 Sep;63(9):814-823. doi: 10.1590/1806-9282.63.09.814. Review.

33.

The need for a network to establish and validate predictive biomarkers in cancer immunotherapy.

Masucci GV, Cesano A, Eggermont A, Fox BA, Wang E, Marincola FM, Ciliberto G, Dobbin K, Puzanov I, Taube J, Wargo J, Butterfield LH, Villabona L, Thurin M, Postow MA, Sondel PM, Demaria S, Agarwala S, Ascierto PA.

J Transl Med. 2017 Nov 3;15(1):223. doi: 10.1186/s12967-017-1325-2.

34.

Nivolumab Plus Ipilimumab in Patients With Advanced Melanoma: Updated Survival, Response, and Safety Data in a Phase I Dose-Escalation Study.

Callahan MK, Kluger H, Postow MA, Segal NH, Lesokhin A, Atkins MB, Kirkwood JM, Krishnan S, Bhore R, Horak C, Wolchok JD, Sznol M.

J Clin Oncol. 2018 Feb 1;36(4):391-398. doi: 10.1200/JCO.2017.72.2850. Epub 2017 Oct 17.

35.

Melanoma brain metastases treated with stereotactic radiosurgery and concurrent pembrolizumab display marked regression; efficacy and safety of combined treatment.

Anderson ES, Postow MA, Wolchok JD, Young RJ, Ballangrud Å, Chan TA, Yamada Y, Beal K.

J Immunother Cancer. 2017 Oct 17;5(1):76. doi: 10.1186/s40425-017-0282-x.

36.

Efficacy and Safety of Pembrolizumab in Patients Enrolled in KEYNOTE-030 in the United States: An Expanded Access Program.

Gangadhar TC, Hwu WJ, Postow MA, Hamid O, Daud A, Dronca R, Joseph R, O'Day SJ, Hodi FS, Pavlick AC, Kluger H, Oxborough RP, Yang A, Gazdoiu M, Kush DA, Ebbinghaus S, Salama AKS.

J Immunother. 2017 Nov/Dec;40(9):334-340. doi: 10.1097/CJI.0000000000000186.

37.

OncoKB: A Precision Oncology Knowledge Base.

Chakravarty D, Gao J, Phillips SM, Kundra R, Zhang H, Wang J, Rudolph JE, Yaeger R, Soumerai T, Nissan MH, Chang MT, Chandarlapaty S, Traina TA, Paik PK, Ho AL, Hantash FM, Grupe A, Baxi SS, Callahan MK, Snyder A, Chi P, Danila D, Gounder M, Harding JJ, Hellmann MD, Iyer G, Janjigian Y, Kaley T, Levine DA, Lowery M, Omuro A, Postow MA, Rathkopf D, Shoushtari AN, Shukla N, Voss M, Paraiso E, Zehir A, Berger MF, Taylor BS, Saltz LB, Riely GJ, Ladanyi M, Hyman DM, Baselga J, Sabbatini P, Solit DB, Schultz N.

JCO Precis Oncol. 2017 Jul;2017. doi: 10.1200/PO.17.00011. Epub 2017 May 16.

38.

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.

Wolchok JD, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob JJ, Cowey CL, Lao CD, Wagstaff J, Schadendorf D, Ferrucci PF, Smylie M, Dummer R, Hill A, Hogg D, Haanen J, Carlino MS, Bechter O, Maio M, Marquez-Rodas I, Guidoboni M, McArthur G, Lebbé C, Ascierto PA, Long GV, Cebon J, Sosman J, Postow MA, Callahan MK, Walker D, Rollin L, Bhore R, Hodi FS, Larkin J.

N Engl J Med. 2017 Oct 5;377(14):1345-1356. doi: 10.1056/NEJMoa1709684. Epub 2017 Sep 11. Erratum in: N Engl J Med. 2018 Nov 29;379(22):2185.

39.

Efficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized Phase II and III Trials.

Schadendorf D, Wolchok JD, Hodi FS, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob JJ, Cowey CL, Lao CD, Chesney J, Robert C, Grossmann K, McDermott D, Walker D, Bhore R, Larkin J, Postow MA.

J Clin Oncol. 2017 Dec 1;35(34):3807-3814. doi: 10.1200/JCO.2017.73.2289. Epub 2017 Aug 25.

40.

Sequential, Multiple Assignment, Randomized Trial Designs in Immuno-oncology Research.

Kidwell KM, Postow MA, Panageas KS.

Clin Cancer Res. 2018 Feb 15;24(4):730-736. doi: 10.1158/1078-0432.CCR-17-1355. Epub 2017 Aug 23.

41.

Measuring Toxic Effects and Time to Treatment Failure for Nivolumab Plus Ipilimumab in Melanoma.

Shoushtari AN, Friedman CF, Navid-Azarbaijani P, Postow MA, Callahan MK, Momtaz P, Panageas KS, Wolchok JD, Chapman PB.

JAMA Oncol. 2018 Jan 1;4(1):98-101. doi: 10.1001/jamaoncol.2017.2391.

42.

Clinical and Morphologic Characteristics of MEK Inhibitor-Associated Retinopathy: Differences from Central Serous Chorioretinopathy.

Francis JH, Habib LA, Abramson DH, Yannuzzi LA, Heinemann M, Gounder MM, Grisham RN, Postow MA, Shoushtari AN, Chi P, Segal NH, Yaeger R, Ho AL, Chapman PB, Catalanotti F.

Ophthalmology. 2017 Dec;124(12):1788-1798. doi: 10.1016/j.ophtha.2017.05.038. Epub 2017 Jul 12.

43.

Endocrine-related adverse events associated with immune checkpoint blockade and expert insights on their management.

Sznol M, Postow MA, Davies MJ, Pavlick AC, Plimack ER, Shaheen M, Veloski C, Robert C.

Cancer Treat Rev. 2017 Jul;58:70-76. doi: 10.1016/j.ctrv.2017.06.002. Epub 2017 Jun 22. Review.

44.

Health-related quality of life results from the phase III CheckMate 067 study.

Schadendorf D, Larkin J, Wolchok J, Hodi FS, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob JJ, Cowey CL, Lao C, Wagstaff J, Callahan MK, Postow MA, Smylie M, Ferrucci PF, Dummer R, Hill A, Taylor F, Sabater J, Walker D, Kotapati S, Abernethy A, Long GV.

Eur J Cancer. 2017 Sep;82:80-91. doi: 10.1016/j.ejca.2017.05.031. Epub 2017 Jun 23.

45.

T-cell invigoration to tumour burden ratio associated with anti-PD-1 response.

Huang AC, Postow MA, Orlowski RJ, Mick R, Bengsch B, Manne S, Xu W, Harmon S, Giles JR, Wenz B, Adamow M, Kuk D, Panageas KS, Carrera C, Wong P, Quagliarello F, Wubbenhorst B, D'Andrea K, Pauken KE, Herati RS, Staupe RP, Schenkel JM, McGettigan S, Kothari S, George SM, Vonderheide RH, Amaravadi RK, Karakousis GC, Schuchter LM, Xu X, Nathanson KL, Wolchok JD, Gangadhar TC, Wherry EJ.

Nature. 2017 May 4;545(7652):60-65. doi: 10.1038/nature22079. Epub 2017 Apr 10.

46.

Neutrophil to Lymphocyte Ratio is Associated With Outcome During Ipilimumab Treatment.

Cassidy MR, Wolchok RE, Zheng J, Panageas KS, Wolchok JD, Coit D, Postow MA, Ariyan C.

EBioMedicine. 2017 Apr;18:56-61. doi: 10.1016/j.ebiom.2017.03.029. Epub 2017 Mar 24.

47.

Elevated Blood Neutrophil-to-Lymphocyte Ratio: A Readily Available Biomarker Associated with Death due to Disease in High Risk Nonmetastatic Melanoma.

Davis JL, Langan RC, Panageas KS, Zheng J, Postow MA, Brady MS, Ariyan C, Coit DG.

Ann Surg Oncol. 2017 Jul;24(7):1989-1996. doi: 10.1245/s10434-017-5836-0. Epub 2017 Mar 16.

48.

A step forward for patients with NRAS-mutant melanoma.

Postow MA, Chapman PB.

Lancet Oncol. 2017 Apr;18(4):414-415. doi: 10.1016/S1470-2045(17)30172-9. Epub 2017 Mar 9. No abstract available.

49.

Patient perspectives on ipilimumab across the melanoma treatment trajectory.

Shuk E, Shoushtari AN, Luke J, Postow MA, Callahan M, Harding JJ, Roth KG, Flavin M, Granobles A, Christian J, Gold G, Schoenhammer M, Gordon M, Cimaglia N, Dyson R, Goodman-Davis N, Colgan MN, Jefferson IS, Munhoz R, D'Angelo S, Wolchok J, Chapman P, Chi P, Carvajal RD, Hay JL.

Support Care Cancer. 2017 Jul;25(7):2155-2167. doi: 10.1007/s00520-017-3621-z. Epub 2017 Mar 1.

50.

A case report of disappearing pigmented skin lesions associated with pembrolizumab treatment for metastatic melanoma.

Wolner ZJ, Marghoob AA, Pulitzer MP, Postow MA, Marchetti MA.

Br J Dermatol. 2018 Jan;178(1):265-269. doi: 10.1111/bjd.15354. Epub 2017 Sep 21.

Supplemental Content

Loading ...
Support Center